MIAMI (PRWEB) December 20, 2017
Aegle Therapeutics Corp. announces the election of Dr. Robert Ryan to its Board of Directors, effective immediately.
"We are pleased to welcome Dr. Robert Ryan to Aegle’s Board," said Shelley A. Hartman, Chief Executive Officer of Aegle Therapeutics. "Robert's deep experience in various skin diseases and pathological conditions including epidermolysis bullosa, along with his extensive global regulatory experience will be invaluable to Aegle."
Dr. Ryan has more than 27 years of research, development and regulatory experience in the pharmaceutical and biotech industries. He currently serves as President and CEO of Innova Therapeutics. Prior to Innova, Dr. Ryan served as President and CEO of Scioderm, a company he founded focused on developing a therapy for the rare disease epidermolysis bullosa. Scioderm was sold to Amicus Therapeutics for upfront payments and milestones totaling approximately $957 million.
Dr. Ryan also served in senior development and regulatory positions at Roche, Bristol-Myers Squibb (BMS), UCB, Atherogenics, Pfizer and Quintiles. Dr. Ryan graduated with a PhD from the University of North Carolina at Chapel Hill, and has advanced degrees in Genetics and Pharmacokinetics.
About Aegle Therapeutics Corp.
Aegle Therapeutics is a regenerative medicine company developing novel therapeutics based on our proprietary extracellular vesicle isolation technology. The company is isolating extracellular vesicles secreted by bone marrow derived mesenchymal stem cells to harness the regenerative healing power of stem cells without using the cells as therapy. Its extracellular vesicle therapy is being developed to treat burns, scarring, epidermolysis bullosa and chronic wounds as well as other indications such as stroke.
Aegle’s proprietary isolation process is easy to scale, low cost and produces extracellular vesicles with an extended shelf life. For more information, visit http://www.aegletherapeutics.com.
Chief Financial Officer